Group 1 - The company has not engaged in drug development and has no plans to establish an AI drug laboratory as of January 16, 2026 [1] - As of January 14, 2026, the company reported that its WiNGPT-related products have secured some customer contracts, but these are still in the early stages, with the total contract amount being a small percentage of the company's overall contracts [1] - The company disclosed that as of January 9, 2026, it had 117,924 shareholders, highlighting its core advantages in the medical information technology sector [1] Group 2 - According to a report by IDC published in July 2025, the company held a 12.6% market share in China's core hospital system market in 2024, maintaining the top position for five consecutive years [1] - The company has clarified that it has no current plans regarding the brain-computer interface sector as of January 7, 2026 [2] - The company's "Waning Pay" system has integrated with Alipay for medical payment services, charging hospitals service fees or commissions based on different circumstances [1]

Group 1 - The core viewpoint of the article is that the company, Weining Health, has developed AI models and related medical AI products, which have started to secure some customer contracts, but revenue generation is still in the early stages [1] - The company indicated that the cumulative contract amount for its AI products is currently low and represents a small proportion of the overall contract amount [1]

Core Viewpoint - The company acknowledges that its AI products, including WiNGPT-related offerings, have secured some customer contracts, but revenue generation is still in the early stages and the total contract amount remains low compared to the overall contract value [1]. Group 1 - The company has a significant amount of medical data assets and advanced AI technology [1]. - The AI large model and related medical AI products have obtained some customer contracts [1]. - The cumulative contract amount for these AI products is still relatively small and constitutes a low proportion of the company's total contract amount [1].